ライフサイエンスコーパス: germ cell tumor

1 ion, and 15 (50%) had recurrence with viable germ cell tumor.

2 ma, rhabdomyosarcoma, a breast cancer, and a germ cell tumor.

3 approach from the Brazilian GCT-99 study on germ cell tumors.

4 earched using the terms testicular cancer or germ cell tumors.

5 icities of initial treatments for testicular germ cell tumors.

6 reading frame and is expressed in human male germ cell tumors.

7 at occur in vivo, particularly in testicular germ cell tumors.

8 therapies are being explored in early stage germ cell tumors.

9 so with the different histologic subtypes of germ cell tumors.

10 r potential toxicities, in the management of germ cell tumors.

11 are continuing to identify risk factors for germ cell tumors.

12 nt pre-clinical and clinical developments in germ cell tumors.

13 by autologous stem-cell transplantations for germ cell tumors.

14 d-dose etoposide as salvage chemotherapy for germ cell tumors.

15 in patients with mastocytosis, leukemia, and germ cell tumors.

16 to overcome the rapid proliferation seen in germ cell tumors.

17 ure teratoma as one component of their mixed germ cell tumors.

18 expressed in human pluripotent cells and in germ cell tumors.

19 loss in one or more components of the mixed germ cell tumors.

20 umors that often coexist with other types of germ cell tumors.

21 nt as in mice and a potential involvement in germ cell tumors.

22 ldren with newly diagnosed non-germinomatous germ cell tumors.

23 with pathological stage II or III testicular germ cell tumors.

24 ldren with newly diagnosed non-germinomatous germ cell tumors.

25 seminomatous and nonseminomatous testicular germ cell tumors.

26 ute myeloid leukemia (AML), mastocytosis and germ cell tumors.

27 in patients with mastocytosis, leukemia, and germ cell tumors.

28 ich can form noninfectious particles in some germ cell tumors.

29 citabine in heavily pretreated patients with germ cell tumors.

30 rate and survival in patients with poor-risk germ cell tumors.

31 standard treatment for advanced disseminated germ cell tumors.

32 essed in specific histopathologic subsets of germ cell tumors.

33 e patients with extragonadal nonseminomatous germ cell tumors.

34 dren with standard risk medulloblastomas and germ cell tumors.

35 ly as either seminomas or nonseminomas/mixed germ cell tumors.

36 reatment of certain categories of testicular germ cell tumors.

37 infertility and are associated with ovarian germ cell tumors.

38 reatment of certain categories of testicular germ cell tumors.

39 reatment of certain categories of testicular germ cell tumors.

40 ller men are at increased risk of testicular germ-cell tumors.

41 exposure to pesticides and risk of childhood germ-cell tumors.

42 (testicular teratocarcinomas) and low in non-germ-cell tumors.

43 , central nervous system tumors, or renal or germ-cell tumors.

44 nd is a key determinant of oncogenic fate in germ-cell tumors.

45 in only 35% of patients with newly diagnosed germ-cell tumors.

46 g criteria: (1) history of malignant ovarian germ cell tumor; (2) treatment with surgery plus platinu

47 eat success in the treatment of disseminated germ cell tumors, 20% of patients are incurable and beco

48 brile neutropenia following chemotherapy for germ cell tumors (44.5% v 36.0%).

49 a or primitive neuroectodermal tumors, 57.8; germ cell tumors, 63.5; ependymoma or high-grade glioma,

50 135 patients with progressive, disseminated germ cell tumors after cisplatin-etoposide-based combina

51 ticide exposure in the workplace and risk of germ-cell tumors among offspring.

52 hown activity as single agents in refractory germ cell tumors and can be combined with manageable tox

53 Two non-AIDS-defining cancers, germ cell tumors and Hodgkin's disease, have been report

54 cause of cisplatin resistance in testicular germ cell tumors and may also be implicated in ovarian a

55 Expression of MBD3L2 was found in germ cell tumors and some somatic tissues.

56 in the geographic and ethnic distribution of germ cell tumors and the changing incidence of seminoma

57 The genetic nature of testicular germ cell tumors and the molecular mechanisms underlying

58 lude thyroid, thymic and lymph node lesions; germ cell tumors and vascular lesions.

59 In addition, germ-cell tumors and a few somatic tumors show detectabl

60 c pollution in relation to retinoblastoma or germ cell tumors, and both cancers are rare, these findi

61 M50B expression is deregulated in testicular germ cell tumors, and loss of imprinting occurs frequent

62 umor, 17 had malignant astrocytoma, nine had germ-cell tumor, and 21 had other types of tumors) were

63 Germ cell tumors are a heterogeneous group of neoplasms

64 ations in the rising incidence of testicular germ cell tumors are beginning to be observed in certain

65 Gonadal and nongonadal germ cell tumors are derived from primordial germ cells

66 Germ cell tumors are highly treatable, but significant c

67 opriate Phf7 expression, is also observed in germ cell tumors arising from the loss of bag of marbles

68 OCT4 is commonly expressed in germ-cell tumors as well as putative cancer stem cells i

69 fying potentially new serum tumor markers in germ cell tumor, as well as the role of the traditional

70 Odds ratios for childhood germ-cell tumors associated with maternal exposures befo

71 Patients with germ cell tumors believed to be incurable with chemother

72 whether the humoral immune response affects germ cell tumor biology.

73 HERV-K viral genes are highly transcribed in germ cell tumors but are transcribed to lower or undetec

74 ic, normal fetal kidney, and endometrial and germ cell tumors) but little sequence similarity to othe

75 In germ cell tumors, carboplatin was inferior because of lo

76 ssion profiles of human ES cell lines, human germ cell tumor cell lines and tumor samples, somatic ce

77 We analyzed three pairs of testicular germ cell tumor cell lines using Affymetrix expression m

78 Analysis of testicular germ cell tumor clinical samples by quantitative reverse

79 between mature teratoma and all of the other germ cell tumor components were seen in 10 of 14 tumors

80 ogenetic relationship of teratoma with other germ cell tumor components.

81 uman spermatogenesis and in human testicular germ cell tumors considered to be precursors of EC.

82 Germ cell tumors constitute the most curable of all canc

83 egies for the different stages of testicular germ cell tumors continue to be defined and refined, as

84 ionally, risk factors for the development of germ cell tumors continue to be identified.

85 tissue specimens and cell culture models of germ cell tumors continues.

86 Immunohistochemical results from 43 germ cell tumors demonstrated increased FGF4 expression

87 ifferentiation may be of predictive value in germ cell tumor diagnosis.

88 The extragonadal germ cell tumors (EGCTs) represent a unique entity, and

89 rapeutic role for 4HPR mediated apoptosis in germ cell tumors even when a maturation block is present

90 ent studies on the molecular pathogenesis of germ cell tumors further highlight the complexity of the

91 t-line treatment in patients with metastatic germ cell tumor (GCT) and poor-prognostic clinical featu

92 Purpose Patients with relapsed metastatic germ cell tumor (GCT) can be cured with second-line and

93 Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associ

94 Germ cell tumor (GCT) is the most common malignancy in y

95 Of these, 269 (51%) had either viable germ cell tumor (GCT) or teratoma present in the RPLND s

96 chorionic gonadotrophin in the management of germ cell tumor (GCT) patients is a biochemical reflecti

97 lus etoposide [E] with stem-cell support) in germ cell tumor (GCT) patients predicted to have a poor

98 ring the first two cycles of chemotherapy in germ cell tumor (GCT) patients was initially reported by

99 malities in postchemotherapy nonseminomatous germ cell tumor (GCT) patients.

100 es were conducted on 488 North American male germ cell tumor (GCT) survivors in relation to cumulativ

101 MT of a somatic teratomatous component in a germ cell tumor (GCT) to a histology that is identical t

102 alysis of patients with late relapse (LR) of germ cell tumor (GCT) with reports on clinical character

103 trial for patients with cisplatin-refractory germ cell tumor (GCT).

104 Radiation therapy for CNS germ cell tumors (GCT) is commonly associated with neuro

105 ubicin (CIS-EPI) in patients with metastatic germ cell tumors (GCT) not amenable to cure with standar

106 Malignant germ cell tumors (GCT) of childhood are rare and heterog

107 r clinicopathologic heterogeneity, malignant germ cell tumors (GCT) share molecular abnormalities tha

108 chemotherapy (HDCT) as salvage modality for germ cell tumors (GCT) were previously described, and a

109 After resection, 26 patients had germ cell tumors (GCT), 12 had malignant transformation

110 eatment in patients with newly diagnosed CNS germ cell tumors (GCT), using etoposide plus cisplatin f

111 y sensitivity, most patients with metastatic germ cell tumors (GCTs) are cured with cisplatin-based c

112 The anterior mediastinal germ cell tumors (GCTs) are the most common EGCT.

113 Male germ cell tumors (GCTs) are uniquely sensitive to cispla

114 Adult male germ cell tumors (GCTs) arise by transformation of totip

115 are rare in children, with pineoblastoma and germ cell tumors (GCTs) being the most common.

116 Pediatric germ cell tumors (GCTs) commonly arise at extragonadal s

117 Adult male germ cell tumors (GCTs) comprise distinct groups: semino

118 Male adult germ cell tumors (GCTs) comprise two major histologic gr

119 ssion by immunohistochemistry in sections of germ cell tumors (GCTs) from 10 patients with testicular

120 tes for children with extracranial malignant germ cell tumors (GCTs) have increased significantly.

121 rain mice are predisposed to developing male germ cell tumors (GCTs) of the testes.

122 Germ cell tumors (GCTs) of the testis are the predominan

123 gosity (LOH) studies of chromosome 5 in male germ cell tumors (GCTs) previously reported suggested th

124 Adult human male germ cell tumors (GCTs) provide a unique opportunity to

125 ternal dietary intake patterns and pediatric germ cell tumors (GCTs) using principal components analy

126 CRs) in two thirds of patients with advanced germ cell tumors (GCTs) who relapsed after first-line ch

127 py, a mainstay of treatment for disseminated germ cell tumors (GCTs), is associated with venous throm

128 12q22 region is recurrently deleted in male germ cell tumors (GCTs), suggesting that this site may h

129 e to chemotherapy for patients with advanced germ cell tumors (GCTs), to evaluate different methods b

130 herapy for patients with relapsed testicular germ cell tumors (GCTs).

131 minomas and dysgerminomas, a subset of human germ cell tumors (GCTs).

132 irst-line therapy in patients with poor-risk germ cell tumors (GCTs).

133 n has previously been reported in human male germ cell tumors (GCTs).

134 therapy (HDCT) in the management of advanced germ cell tumors (GCTs).

135 Germ-cell tumors (GCTs), which arise from pluripotent em

136 , intermediate immature teratomas, malignant germ cell tumors [GCTs (dysgerminomas, endodermal sinus

137 genome-wide association study for testicular germ cell tumor, genotyping 298,782 SNPs in 979 affected

138 our patients with testicular nonseminomatous germ cell tumor had low-volume retroperitoneal metastase

139 The medical treatment of advanced testicular germ cell tumors has changed over the past 30 years, wit

140 Patients with clinical stage I testicular germ cell tumors have been managed with adjuvant radioth

141 wide spectrum of human neoplasms, including germ cell tumors, high-grade and low-grade carcinomas an

142 cs were compared for patients who had either germ cell tumor histology at surgery or relapsed at the

143 (TGCTs), suggesting similar etiology between germ cell tumors in mouse and man.

144 several important developments in testicular germ cell tumors in the last year.

145 several important developments in testicular germ cell tumors in the past year is provided.

146 several important developments in testicular germ cell tumors in the past year.

147 several important developments in testicular germ cell tumors in the past year.

148 several important developments in testicular germ cell tumors in the past year.

149 to pesticides during the index pregnancy and germ-cell tumors in boys (OR = 0.2, 95% CI: 0.1, 1.0).

150 ides during the postnatal period and risk of germ-cell tumors in girls (OR = 2.3, 95% CI: 1.0, 5.2) a

151 or patients with intermediate- and poor-risk germ cell tumors, in whom 4 cycles of bleomycin, etoposi

152 ations in 1 of 14 nonseminomatous testicular germ-cell tumors, in 2 of 5 embryonal rhabdomyosarcomas,

153 dies show changes in the ethnic incidence of germ cell tumors; in particular, African-Americans have

154 iable region from 320 sequences expressed by germ cell tumor-infiltrating B cells revealed clear evid

155 confidence interval (CI): 2.65, 3.50), with germ cell tumors (IRR = 5.19, 95% CI: 2.67, 9.41), retin

156 minal residual masses after chemotherapy for germ cell tumors is both a feasible and safe alternative

157 ons between chlordane isomers and testicular germ cell tumors, it is reasonable to assume that chlord

158 Secondly, a subset of testicular germ cell tumors, known as non-seminomas, often contain

159 However, chemotherapy of germ-cell tumors led to the induction of anti-OCT4 immun

160 lignancies include lung cancer, skin cancer, germ cell tumors, leiomyosarcomas, cancers of the head a

161 is, pooled libraries (with testis), and in a germ cell tumor library.

162 scents with intermediate-risk (IR) malignant germ cell tumors (MGCT) if the administration of cisplat

163 contemporary management of malignant ovarian germ cell tumors (MOGCT).

164 , recent studies demonstrate that testicular germ cell tumor mortalities can vary significantly in di

165 e survival outcomes in metastatic testicular germ cell tumor (MT-GCT), but how the initial risk chang

166 intermediate risk, poor risk, and recurrent germ cell tumors need to be developed, while long-term t

167 r of 12 patients (33%) with nongerminomatous germ cell tumors (NGGCTs) survived without evidence of d

168 f patients with disseminated nonseminomatous germ cell tumor (NSGCT) managed under a postchemotherapy

169 in patients with metastatic nomseminomatous germ cell tumor (NSGCT) of the testis.

170 management of patients with nonseminomatous germ cell tumor (NSGCT) who achieve a serologic and radi

171 nical stage (CS) IIA and IIB nonseminomatous germ cell tumor (NSGCT) with adenopathy more than 2 cm,

172 went PC-RPLND for metastatic nonseminomatous germ cell tumor (NSGCT).

173 y and surgery for metastatic nonseminomatous germ cell tumors (NSGCT) results in survival rates of gr

174 patients with poor-prognosis nonseminomatous germ cell tumors (NSGCT) treated with CBOP/BEP.

175 ients from 1989 to 2003 with nonseminomatous germ cell tumors (NSGCT) who underwent initial PC-RPLND

176 ovarian dysgerminoma and 37 non-seminomatous germ cell tumors (NSGCT).

177 with clinical stage I (CS1) nonseminomatous germ cell tumors (NSGCT); this study examined whether an

178 tients with clinical stage I nonseminomatous germ cell tumors (NSGCTs) have been managed with surveil

179 th poor-prognosis metastatic nonseminomatous germ cell tumors (NSGCTs).

180 birth of the index child were not related to germ-cell tumors (odds ratios (ORs) were 0.9 (95% CI: 0.

181 The most common malignant germ cell tumor of early childhood is the endodermal sin

182 .A 32-year-old man with a history of a mixed germ cell tumor of the testis presented with acute-onset

183 tic linkage to the development of testicular germ cell tumors of adolescents and adults (TGCTs), i.e.

184 Salvage therapy for disseminated germ cell tumors of all histologic subtypes with vinblas

185 Extragonadal germ cell tumors of infancy, one of the most common neon

186 rates that has been implicated in testicular germ cell tumors of mouse and human.

187 Germ cell tumors of the ovary constitute less than one p

188 tidisciplinary approach to the management of germ cell tumors of the testis has resulted in survival

189 tients with clinical stage I nonseminomatous germ cell tumors of the testis were entered on a surveil

190 marize the surgical management of metastatic germ cell tumors of the testis, highlighting the indicat

191 oma with other components of malignant mixed germ cell tumors of the testis.

192 Primary germ-cell tumors of the central nervous system are rare

193 mic, and brainstem encephalitis, and 78% had germ-cell tumors of the testis.

194 Like several other tumor types, germ cell tumors often harbor an immune cell infiltrate

195 ion of health care resources between ovarian germ cell tumor (OGCT) survivors and age/race/education-

196 Ovarian germ cell tumors (OGCTs) show a heterogeneity that is no

197 erived from the same element of the original germ cell tumor or the same progenitor cell.

198 odds ratio (OR) = 1.05; 95% CI: 1.01, 1.10]; germ cell tumors (OR = 1.16; 95% CI: 1.04, 1.29), partic

199 her RA-sensitive cell lines that were not of germ cell tumor origin.

200 ng regions of imbalance (SORI) in testicular germ cell tumors other than the 12p region, which has be

201 Preclinical and clinical developments in germ cell tumors over the past year are summarized.

202 the preclinical and clinical developments in germ cell tumors over the past year is presented.

203 GFBP-3 concentrations and risk of testicular germ-cell tumors (p > 0.05).

204 tudies highlight the complexities underlying germ cell tumor pathogenesis.

205 definite activity in this heavily pretreated germ cell tumor patient population.

206 ion of the resected tissue showed metastatic germ cell tumor predominantly consisting of a yolk sac e

207 chromosome 1p33-34, a region deleted in some germ cell tumors, raising the possibility that PTCH2 may

208 gy of nonseminomatous subtypes of testicular germ cell tumors remain to be established.

209 Significant challenges for poor-risk germ cell tumors remain.

210 n in postorchiectomy early-stage nonseminoma germ cell tumors remains a topic of debate.

211 Analysis of human germ cell tumors reveals similar gene expression changes

212 ors examined associations between testicular germ-cell tumor risk and circulating concentrations of i

213 Human germ cell tumors show a strong sensitivity to genetic ba

214 ized the immune cell infiltrate of all three germ cell tumor subtypes and defined the molecular chara

215 quences of therapies in long-term testicular germ cell tumor survivors are being further clarified.

216 To compare malignant ovarian germ cell tumor survivors with a matched control group o

217 TRs was found to be high in human and murine germ cell tumors (testicular teratocarcinomas) and low i

218 Complex genetic factors underlie testicular germ cell tumor (TGCT) development.

219 wide association (GWA) studies of testicular germ cell tumor (TGCT) have identified 18 susceptibility

220 Testicular germ cell tumor (TGCT) is the most common cancer in youn

221 Testicular germ cell tumor (TGCT) is the most common cancer in youn

222 Unconventional inheritance for testicular germ cell tumor (TGCT) risk both in humans and mice impl

223 exhibit male infertility, a known testicular germ cell tumor (TGCT) risk factor.

224 are the most potent modifiers of testicular germ cell tumor (TGCT) susceptibility in mice and rats.

225 enetic modifier known to suppress testicular germ cell tumor (TGCT) susceptibility in mice or humans.

226 etic variants act as modifiers of testicular germ cell tumor (TGCT) susceptibility in the 129/Sv mous

227 genome-wide association study for testicular germ cell tumor (TGCT), genotyping 307,666 SNPs in 730 c

228 distinct susceptibility loci for testicular germ cell tumor (TGCT).

229 ntify new susceptibility loci for testicular germ cell tumor (TGCT).

230 enome-wide association studies of testicular germ cell tumor (TGCT; 3,558 cases and 13,970 controls)

231 ked disparity in the incidence of testicular germ cell tumors (TGCT) among white and black men for a

232 Testicular germ cell tumors (TGCT) are considered a paradigm of che

233 Testicular germ cell tumors (TGCT) are sex limited, occurring only

234 Testicular germ cell tumors (TGCT) are the most common solid tumors

235 Testicular germ cell tumors (TGCT) are the most frequently diagnose

236 Testicular germ cell tumors (TGCT) generally respond well to chemot

237 Susceptibility to testicular germ cell tumors (TGCT) has a significant heritable comp

238 Testicular germ cell tumors (TGCT) have been expected to have a str

239 etic control of susceptibility to testicular germ cell tumors (TGCT) in humans or mice.

240 Testicular germ cell tumors (TGCT) originate from germ cells.

241 Testicular germ cell tumors (TGCT) represent the most common malign

242 isk factor for the development of testicular germ cell tumors (TGCT), but the initiating event linkin

243 also influences susceptibility to testicular germ cell tumors (TGCT), the most common testicular canc

244 ance and thereby increase risk of testicular germ cell tumors (TGCT).

245 analyzed population-wide data on testicular germ-cell tumor (TGCT) status in 1,135,320 two-generatio

246 Testicular germ cell tumors (TGCTs) are highly responsive to and cu

247 Testicular germ cell tumors (TGCTs) are the most common solid cance

248 Testicular germ cell tumors (TGCTs) arise despite possessing high l

249 netic basis for susceptibility to testicular germ cell tumors (TGCTs) has been remarkably elusive.

250 ) gene enhances susceptibility to testicular germ cell tumors (TGCTs) in mice, in part by interacting

251 ement, and risk stratification of testicular germ cell tumors (TGCTs) in the past year.

252 The etiology of testicular germ cell tumors (TGCTs) is poorly understood, with cryp

253 ial is invariably associated with testicular germ cell tumors (TGCTs) of adolescents and adults, most

254 several important developments in testicular germ cell tumors (TGCTs) over the past year.

255 Testicular germ cell tumors (TGCTs) share germline ancestry but div

256 Susceptibility to spontaneous testicular germ cell tumors (TGCTs), a common cancer affecting youn

257 nderstanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability r

258 es also are misregulated in human testicular germ cell tumors (TGCTs), suggesting similar etiology be

259 Testicular germ cell tumors (TGCTs), the most common neoplasms of y

260 icancer drug for the treatment of testicular germ cell tumors (TGCTs).

261 ociated with an increased risk of testicular germ cell tumors (TGCTs).

262 crocalcifications do exist in roughly 50% of germ cell tumors the majority of men with testicular mic

263 to the known hypersensitivity of testicular germ cell tumors to chemotherapy.

264 evance to the hypersensitivity of testicular germ cell tumors to cisplatin, are discussed.

265 nship to other components of malignant mixed germ cell tumors to gain potential insight into the hist

266 but were indeed found in 7% of 43 testicular germ cell tumor trios; this percentage exceeds backgroun

267 described previously in ARF-null mice (mixed germ cell tumor, Triton tumor, and histiocytic sarcoma)

268 o stem and progenitor cells of patients with germ cell tumors undergoing autologous transplantation.

269 ed its expression levels in human testicular germ cell tumors using patient tissues, model cell lines

270 ion studies were extended to patient-derived germ cell tumors using total cellular RNA Northern analy

271 ar OS in patients with a primary mediastinal germ cell tumor was 77.1% (95% CI, 34.5% to 93.9%) compa

272 high-dose etoposide as therapy for relapsed germ cell tumors was associated with a 2.6% risk of deve

273 o search for clues into the genesis of human germ cell tumors, we compared the expression profiles of

274 Malignant germ cell tumors were identified in 2.8% (31 of 1097) of

275 total of 304 men with advanced disseminated germ cell tumors were randomly allocated to receive four

276 and 90 of 149 patients with nonseminomatous germ-cell tumors were disease-free.

277 49 patients with moderate-stage disseminated germ-cell tumors were randomized to either three or four

278 itive treatment of patients with nonseminoma germ cell tumor, whereas radiotherapy, as a standard tre

279 Twenty patients with germ cell tumor who had persistent disease or relapse fr

280 All CS I patients with nonseminomatous germ cell tumors who underwent RPLND at Indiana Universi

281 The treatment of advanced testicular germ cell tumors with cisplatin combination chemotherapy

282 Germ cell tumors with EC components were significantly m

283 cond-line therapy in patients with recurrent germ cell tumors with previous treatment with cisplatin

284 to 100) of patients with favorable prognosis germ-cell tumor with an initial HCG of < or = 1,000 mIU/

285 mcitabine is an active regimen in refractory germ cell tumors, with an acceptable toxicity profile.

286 4 mRNA (P < or = 0.0179) than other examined germ cell tumors without EC components.